Skip to main content
Erschienen in: BMC Surgery 1/2022

Open Access 01.12.2022 | Research

The effect of the number of hepatic inflow occlusion times on the prognosis of ruptured hepatocellular carcinoma patients after hepatectomy

verfasst von: Feng Xia, Zhiyuan Huang, Elijah Ndhlovu, Mingyu Zhang, Xiaoping Chen, Bixiang Zhang, Peng Zhu

Erschienen in: BMC Surgery | Ausgabe 1/2022

Abstract

Background and aim

It has been previously reported that inflow occlusion does not affect postoperative outcomes in hepatocellular carcinoma patients. However, for patients with ruptured hepatocellular carcinoma(rHCC), the effect of hepatic inflow occlusion and the number of occlusion times on the prognosis is unknown.

Methods

203 patients with ruptured hepatocellular carcinoma were enrolled in this study. They were first divided into the non-hepatic inflow occlusion (non-HIO) group and the hepatic inflow occlusion (HIO) group. The Kaplan–Meier method was used to compare the recurrence-free survival and overall survival between the two groups. Patients in the HIO group were further divided into one-time HIO and two times HIO groups. KM method was also used to compare the two groups. Finally, independent risk factors affecting RFS and OS were determined by multivariate Cox regression analysis.

Result

In the non-HIO group, 1-,3- and 5-year OS rates were 67.0%, 41.0%, and 22.0%respectively, and RFS rates were 45.0%, 31.0%, and 20.0% respectively; In the one-HIO group, the 1-,3-, and 5-year OS rates were 55.1%, 32.1%, and 19.2% respectively, and RFS rates were 33.3%, 16.7%, and 7.7% respectively; In the two-HIO group, 1-,3-, and 5-year OS rates were 24.0%, 0.0%, and 0.0% respectively, and RFS rates were 8.0%, 0.0%, and 0.0% respectively. By Cox regression analysis, HIO was an independent risk factor for a poor prognosis in rHCC patients.

Conclusion

One time hepatic inflow occlusion did not affect postoperative OS, but negatively affected the RFS of rHCC patients; two times hepatic inflow occlusion negatively affected the postoperative OS and RFS in patients with rHCC.
Hinweise

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
BCLC
Barcelona Clinic Liver Cancer
HIO
Hepatic inflow occlusion (HIO)
HbsAg
Hepatitis B surface antigen
AFP
Alpha-fetoprotein
HCC
Hepatocellular carcinoma
rHCC
Ruptured hepatocellular carcinoma
CT
Computed tomography
MRI
Magnetic resonance imaging
RFA
Radiofrequency ablation
TACE
Transcatheter arterial chemoembolization
OS
Overall survival
RFS
Recurrence-free survival
MVI
Microvascular invasion
ALB
Albumin
ALT
Alanine aminotransferase
AST
Aspartate Transaminase
ALP
Alkaline phosphatase.
GGT
Glutamyl transpeptidase

Introduction

Hepatocellular carcinoma (HCC) is one of the most serious cancers in the world and the second leading cause of death due to cancer. Rupture of hepatocellular carcinoma (HCC) is a rare and serious complication of HCC [15]. In recent years, the number of ruptured HCC(rHCC) patients has been increasing year by year, especially in Asia, and the proportion of rupture is much higher than in Europe and the United States. For patients with rHCC, transcatheter arterial chemoembolization (TACE), intraperitoneal chemotherapy, and hepatectomy have been used, but recent studies have shown that two-stage delayed hepatectomy is a relatively better treatment for suitable patients [6, 7]. Although rHCC patients have a good prognosis after hepatectomy, there is still a need to pay attention to their situation because ruptured HCC patients are prone to hemodynamic instability.
Since intraoperative bleeding is the main problem in hepatectomy, and intraoperative blood transfusion may affect the postoperative prognosis of patients, researchers have introduced the method of hepatic blood flow occlusion to control bleeding. At present, the most widely used techniques are the Pringle Maneuver and Hemihepatic inflow occlusion [8, 9]. The Pringle maneuver was first described in 1908 as a method that blocks hilar vessels and achieves the effect of controlling hepatic blood flow by clamping the hepatoduodenal ligament; in 1987, a hemihepatic occlusion (HHO) technique was proposed to control hepatic blood flow [10]. In short, both methods can effectively control hepatic blood flow, but they inevitably cause hepatic hypoperfusion and ischemia–reperfusion injury, and liver dysfunction occurs at the same time [1113]. Patients with ruptured HCC are hemodynamically unstable on admission, and most of them have associated cirrhosis, reducing their tolerance to ischemia. Therefore, hepatic inflow occlusion can affect the liver function of the residual liver after surgery, and it may also affect the long-term prognosis of rHCC patients after surgery.
In the past, Jing-Hang Jiang et al. [14] believed that hepatic inflow occlusion did not affect the postoperative outcomes of HCC patients, while other researchers [15] found that HIO affected postoperative liver function, which in turn made the postoperative prognosis worse. However, the long-term effects of HIO on the prognosis of patients with ruptured HCC are unknown, and the effect of the number of times of HIO on prognosis is also unclear.
In this retrospective study, we aimed to assess the prognostic impact of HIO in patients with ruptured HCC. We also compared the effect of the number of HIO on the overall survival and recurrence-free survival of patients.

Methods

Patients

We retrospectively collected the data of 203 patients who were diagnosed with ruptured HCC and received surgical treatment at Wuhan Tongji Hospital between January 2010 and December 2018. We followed strict inclusion and exclusion criteria; the inclusion criteria were: (1) ruptured liver cancer determined by both contrast-enhanced CT and MRI (2) postoperative diagnosis of HCC confirmed by an experienced pathologist (3) liver function classification in Child–pugh class A or B (4) no invasion of the great vessels of the liver (5) negative resection margin (6) this admission was the first discovery of tumors; the exclusion criteria were: (1) postoperative diagnosis was not HCC (2) patients who had developed metastasis (3) patients who died within one month after surgery. Our research was authorized by the Ethics Committee of Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology (TJ-IRB20210205) [2021/02/04], and all patients gave informed consent.

Propensity score matching analysis

Retrospective studies are prone to selection bias or confounding bias. Therefore, we used propensity score matching to reduce the selected bias. In this study, for patients undergoing hepatic inflow occlusion (HIO), there were differences in one variable. We included the BCLC stage in the propensity score model to balance the baseline. We performed 1:1 matching using SPSS 25.0. We chose a 0.1 caliper width so that an optimal trade-off can be obtained.

Treatment mode

All patients included in the study were operated on by experienced surgeons at our liver surgery center. Whether hepatic inflow occlusion was to be performed was determined by the surgeon according to the intraoperative conditions, the extent of the tumor, and liver fibrosis or cirrhosis [16]. The Pringle Maneuver or hemihepatic vascular occlusion methods were chosen on a case-by-case basis in the HIO group. For these two methods, the time of each blocking was strictly limited to about 15 min, and the release interval was 5 min. Both HIO methods aim to reduce bleeding during parenchymal transection.

Classification of postoperative complications

Because of the wide variety of complications and the relatively small number of patients with complications in each category, we used the Clavien-Dindo complication classification [17].

Follow-up

All patients were followed up every 3 months within the first year and every six months after the second year after discharge, and all examinations included laboratory tests such as liver function, renal function, routine blood tests, tumor markers, and imaging tests such as enhanced abdominal CT and MRI. The time from the first day after operation to death or the last follow-up was defined as the overall survival (OS) rate, and the time from the first day after operation to the discovery of new lesions by physical and clinical examinations or the last follow-up was defined as the recurrence-free survival (RFS) rate. We set the time of the last follow-up to July 30, 2021.

Data analysis

Continuous variables conforming to normal distribution are expressed by (mean ± standard deviation), and continuous variables not conforming to normal distribution are expressed by median (range). The differences between the two groups were compared using the independent samples t-test and Mann–Whitney U test, respectively, and the categorical data were analyzed using a fourfold table and a chi-square test. OS and RFS were calculated using the Kaplan–Meier method, and risk factors for OS and RFS were screened out by univariate and multivariate Cox regression. SPSS 25.0 statistical software and R (version 4.0.5, R Foundation for Statistical Computing, Vienna, Austria) were used for data processing.

Results

Basic characteristics of patients in the hepatic inflow occlusion (HIO) and non-HIO groups (before and after PSM)

A total of 203 patients with ruptured HCC were enrolled. The baseline data are shown in Table 1. We included gender, age, tumor length, tumor number, BCLC stage, Child–pugh classification of liver function, alpha-fetoprotein (AFP), Edmondson-Steiner classification, tumor necrosis, local tumor invasion, preoperative albumin (ALB), alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), glutamyl transferase (GGT), HBsAg and other variables. Only the difference in the BCLC stage (P = 0.009) between the two groups was of statistical significance. The mean age of patients in the HIO group was 42.8 ± 11.4 years and 92.2% were male; the mean age of patients in the non-HIO group was 43.9 ± 11.7 years and 85.0% were male. Nearly 90% of all patients were HBsAg positive (Table 1). After 1:1 PSM correction, all variables in the non-HIO group were balanced, and the BCLC stage was not statistically different between the two groups (P = 1.000) (Table 2).
Table 1
Clinicopathological variables of ruptured HCC patients who underwent hepatectomy with hepatic inflow occlusion(HIO) and without hepatic inflow occlusion(non-HIO)
Variables
Non-hepatic inflow occlusion
Hepatic inflow occlusion
p-value
n = 100
n = 103
Gender (%)
  
0.104
 Male
85 (85.0)
95 (92.2)
 
 Female
15 (15.0)
8 (7.8)
 
Age (y)
43.9 ± 11.7
42.8 ± 11.4
0.498
Length (%)
  
0.437
  ≤ 5 cm
26 (26.0)
22 (21.4)
 
  > 5 cm
74 (74.0)
81 (78.6)
 
Tumor number(%)
  
0.397
 Single
81 (81.0)
78 (75.7)
 
 Multiple
19 (19.0)
25 (24.3)
 
BCLC stage (%)
  
0.009
 A
67 (67.0)
49 (47.6)
 
 B
20 (20.0)
25 (24.3)
 
 C
13 (13.0)
29 (28.2)
 
Child–Pugh (%)
  
0.219
 A
84 (84.0)
79 (76.7)
 
 B
16 (16.0)
24 (23.3)
 
AFP (%)
  
0.470
  ≤ 400 ng/ml
39 (39.0)
35 (34.0)
 
  > 400 ng/ml
61 (61.0)
68 (66.0)
 
Edmondson-steiner(%)
  
0.057
 I
13 (13.0)
8 (7.8)
 
 II
36 (36.0)
54 (52.4)
 
 III
33 (33.0)
21 (20.4)
 
 IV
18 (18.0)
20 (19.4)
 
Necrosis (%)
  
0.086
 No
68 (68.0)
81 (78.6)
 
 Yes
32 (32.0)
22 (21.4)
 
Local invasion (%)
  
0.437
 No
46 (46.0)
53 (51.5)
 
 Yes
54 (54.0)
50 (48.5)
 
ALB(g/L)
35.2 (32.3–38.6)
35.9 (33.1–38.8)
0.516
ALT(U/L)
27.0 (21.0–41.0)
28.0 (21.0–41.0)
0.548
AST(U/L)
36.5 (28.0–61.3)
37.0 (24.0–66.0)
0.919
ALP(U/L)
76.0 (56.0–93.0)
75.0 (61.0–93.0)
0.223
GGT(U/L)
47.0 (28.3–91.0)
58.0 (36.0–129.0)
0.074
HBsAg(%)
  
0.078
 No
17 (17.0)
9 (8.7)
 
 Yes
83 (83.0)
94 (91.3)
 
BCLC, Barcelona Clinic Liver Cancer; AFP, alpha fetoprotein; ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT, γ-glutamyl transpeptidase; HIO, hepatic inflow occlusion
Table 2
Clinicopathological variables of ruptured HCC patients who underwent hepatectomy with hepatic inflow occlusion(HIO) and without hepatic inflow occlusion(non-HIO) after PSM
Variables
Non-hepatic inflow occlusion
Hepatic inflow occlusion
p-value
n = 80
n = 80
Gender (%)
  
0.175
 Male
65 (81.3)
72 (90.0)
 
 Female
15 (18.7)
8 (10.0)
 
Age (y)
45.6 ± 11.4
44.4 ± 11.3
0.568
Length (%)
  
0.858
  ≤ 5 cm
21 (26.3)
22 (27.5)
 
  > 5 cm
59 (73.8)
58 (72.5)
 
Tumor number (%)
  
0.855
 Single
61 (76.3)
59 (73.8)
 
 Multiple
19 (23.8)
21 (26.3)
 
BCLC stage (%)
  
1.000
 A
48 (60.0)
48 (60.0)
 
 B
20 (25.0)
20 (25.0)
 
 C
12 (15.0)
12 (15.0)
 
Child–Pugh (%)
  
0.454
 A
64 (80.0)
59 (73.8)
 
 B
16 (20.0)
21 (26.3)
 
AFP (%)
  
0.748
  ≤ 400 ng/ml
31 (38.8)
34 (42.5)
 
  > 400 ng/ml
49 (61.3)
46 (57.5)
 
Edmondson-steiner (%)
  
0.091
 I
11 (13.8)
7 (8.8)
 
 II
28 (35.0)
43 (53.8)
 
 III
26 (32.5)
16 (20.0)
 
 IV
15 (18.8)
14 (17.5)
 
Necrosis (%)
  
0.205
 No
56 (70.0)
63 (78.8)
 
 Yes
24 (30.0)
17 (21.3)
 
Local invasion (%)
  
0.635
 No
36 (45.0)
40 (50.0)
 
 Yes
44 (55.0)
40 (50.0)
 
ALB (g/L)
35.3 (32.3–38.1)
35.6 (32.9–37.8)
0.889
ALT (U/L)
27.0 (21.0–43.3)
30.5 (24.0–44.0)
0.321
AST (U/L)
37.5 (28.5–63.5)
35.0 (22.3–65.8)
0.512
ALP (U/L)
76.0 (54.5–94.5)
76.5 (61.0–91.0)
0.475
GGT (U/L)
49.5 (28.0–93.3)
51.5 (35.0–126.8)
0.280
HBsAg (%)
  
0.159
 No
14 (17.5)
7 (8.8)
 
 Yes
66 (82.5)
73 (91.3)
 
BCLC, Barcelona Clinic Liver Cancer; AFP, alpha fetoprotein; ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT, γ-glutamyl transpeptidase; HIO, hepatic inflow occlusion; PSM, Propensity Score Matching

Intraoperative and postoperative clinical results

In the non-HIO group, the average blood loss was 441 ± 183.5 ml, the average operation time was 321 ± 133.7 min, 41 patients had postoperative complications; in the HIO group, the average blood loss was 498.2 ± 258.3 ml, the average operation time was 305.4 ± 121.8 min, 36 patients had postoperative complications. There was no statistical difference in blood loss, operation time, and postoperative complications between the non-HIO group and the HIO group (Table 3).
Table 3
Comparison of intraoperative and postoperative findings
 
Non-hepatic inflow occlusion
hepatic inflow occlusion
P
Blood loss (ml)
  
0.071
 Mean(SD)
441.0(183.5)
498.2(258.3)
 
 Median (range[25%–75%])
282 (100–1200)
312 (80–1800)
 
Duration of operation (min)
  
0.386
 Mean(SD)
321.0(133.7)
305.4(121.8)
 
 Median (range[25%-75%])
279 (135–480)
298 (144–534)
 
Dindo–Clavien morbidity
  
0.432
Grades I–IV
41
36
 
 I
16
17
 
 II
21
12
 
 III
3
6
 
  IIIa
3
5
 
  IIIb
0
1
 
 IV
0
1
 
 V
1
0
 
SD, standard deviation

Comparison of the OS and RFS in the HIO and non-HIO groups

In the HIO group, the median survival time was 358.0 days, the 1-, 3-, and 5-year OS rates were 47.6%, 24.2%, and 14.6% respectively; the 1-, 3-, and 5-year RFS rates were 27.2%, 12.6%, and 5.8% respectively; In the non-HIO group, the median survival time was 730 days, the 1-, 3-, and 5-year OS rates were 67.0%, 41.0%, and 22.0% respectively; the 1-, 3-, and 5-year RFS rates were 45.0%, 31.0%, and 20.0% respectively.
Survival curves were plotted by the K-M method, and the OS (P = 0.007, HR = 1.52 (1.12–2.05)) and RFS (P = 0.001; HR = 1.82 (1.33–2.49)) were statistically different between the two groups (Fig. 1A and B). After PSM,survival curves were plotted by the K-M method, and the OS (P = 0.038, HR = 1.43 (1.02–2.02)) and RFS (P = 0.005; HR = 1.65 (1.17–2.33)) were also statistically different between the two groups (Fig. 1C and D).

Basic characteristics of the patients in the one-time hepatic inflow occlusion group(one-HIO) and the two-times hepatic inflow occlusion group(two-HIO)

The HIO group was subdivided into the one-time HIO group (n = 78) and the two-times HIO group (n = 25. The included variables were the same as above. There was no statistical difference in all variables between the two groups (P > 0.05) (Table 4).
Table 4
Clinicopathological variables of ruptured HCC patients who underwent hepatectomy with one-time hepatic inflow occlusion(one-HIO) and two times hepatic inflow occlusion(two-HIO)
Variables
One time hepatic inflow occlusion
Two times hepatic inflow occlusion
p-value
n = 78
n = 25
Gender (%)
  
0.077
 Male
74 (94.9)
21 (84.0)
 
 Female
4 (5.1)
4 (16.0)
 
Age (y)
43.9 ± 11.4
39.1 ± 11.0
0.498
Length (%)
  
0.061
  ≤ 5 cm
20 (25.6)
2 (8.0)
 
  > 5 cm
58 (74.4)
23 (92.0)
 
Tumor number (%)
  
0.567
 Single
58 (74.4)
20 (80.0)
 
 Multiple
20 (25.6)
5 (20.0)
 
BCLC stage (%)
  
0.2
 A
41 (52.6)
8 (32.0)
 
 B
17 (21.8)
8 (32.0)
 
 C
20 (25.6)
9 (36.0)
 
Child–Pugh (%)
  
0.654
 A
59 (75.6)
20 (80.0)
 
 B
19 (24.4)
5 (20.0)
 
AFP (%)
  
0.093
  ≤ 400 ng/ml
31 (39.7)
5 (20.0)
 
  > 400 ng/ml
47 (60.3)
21 (84.0)
 
Edmondson-steiner (%)
  
0.115
 I
7 (9.0)
1 (4.0)
 
 II
45 (57.7)
9 (36.0)
 
 III
14 (17.9)
7 (28.0)
 
 IV
12 (15.4)
8 (32.0)
 
Necrosis (%)
  
0.136
 No
64 (82.1)
17 (68.0)
 
 Yes
14 (17.9)
8 (32.0)
 
Local invasion (%)
  
0.188
 No
43 (55.1)
10 (40.0)
 
 Yes
35 (44.9)
15 (60.0)
 
ALB (g/L)
35.6 (31.3–38.1)
36.5 (34.3–43.5)
0.053
ALT (U/L)
27.0 (20.5–41.8)
30.0 (24.0–49.0)
0.636
AST (U/L)
35.0 (22.0–65.3)
50.0 (31.5–80.0)
0.017
ALP (U/L)
77.0 (61.0–91.3)
72.0 (61.5–98.0)
0.661
GGT (U/L)
55.5 (36.0–122.3)
58.0 (29.5–147.5)
0.929
HBsAg (%)
  
0.881
 No
7 (9.0)
2 (8.0)
 
 Yes
71 (91.0)
23 (92.0)
 
BCLC, Barcelona Clinic Liver Cancer; AFP, alpha fetoprotein; ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT, γ-glutamyl transpeptidase; HIO, hepatic inflow occlusion

Comparison of the OS and RFS in the one-HIO and two-HIO groups

In the one-HIO group, the median survival time was 469.3 days, the 1-, 3-, and 5-year OS rates were 55.1%, 32.1%, and 19.2% respectively; the 1-, 3-, and 5-year RFS rates were 33.3%, 16.7%, and 7.7% respectively; In the two-HIO group, the median survival time was 257.7 days,the 1-, 3-, and 5-year OS rates were 24.0%, 0.0%, and 0.0% respectively; the 1-, 3-, and 5-year RFS rates were 8.0%, 0.0%, and 0.0% respectively.
We plotted the survival curves using the K-M method, and the OS (P < 0.001, HR = 2.69 (1.63–4.44)) and RFS (P = 0.025, HR = 1.78 (1.07–2.96)) were statistically different between these two groups (Fig. 2).

The one-HIO group and two-HIO group were compared with the non-HIO group for OS and RFS, respectively

According to the survival curve, when the one-HIO and the non-HIO group were compared, there was no statistical difference in OS (P = 0.088) between the two groups, and there was a difference in RFS (P = 0.003 HR = 1.63 (1.18–2.27)) between the two groups (Fig. 2); when the two-HIO and the non-HIO groups were compared, both the OS (P < 0.001, (HR = 3.64 (2.21–5.99)) and the RFS (P < 0.001 HR = 2.67 (1.61–4.43)) were statistically different between the two groups (Fig. 2).

The impact of HIO on the prognosis of ruptured HCC patients was determined using Cox regression

To further determine the effect of HIO and the number of times of HIO on the postoperative prognosis of ruptured HCC patients, we used a multivariate Cox regression model to determine the risk factors affecting the postoperative OS and RFS of ruptured HCC patients.
In all 203 patients, we identified risk factors affecting OS and RFS by univariate and multivariate Cox regression models. In terms of the overall survival, HIO (P < 0.001) was a risk factor for decreased OS, but after stratifying for the number of occlusion times, one-HIO was not a risk factor for decreased OS (P = 0.495), and two-HIO was a risk factor for decreased OS (P < 0.001, HR = 4.116 (2.398–7.065)) (Table 5). For the RFS, not only was HIO (P < 0.001) a risk factor for decreased RFS, but both one-HIO((P = 0.003) HR = 1.643 (1.181–2.285)) and two-HIO ((P < 0.001) HR = 2.501 (1.521–4.112)) were also risk factors for decreased RFS (Table 6).
Table 5
Univariate and multivariate analysis to identify factors that predict overall survival in patients with ruptured hepatocellular carcinoma treated by hepatectomy
 
Univariate analysis
Multivariate analysis
p
HR
95%confidence interval
p
HR
95%confidence interval
Gender
 Male/female
0.427
1.234
0.735–2.070
   
Age
 Per year
0.720
1.003
0.987–1.019
   
Tumor length
 Per cm
0.041
1.636
1.020–2.626
0.013
1.691
1.119–2.554
Tumor number
 Mutiple/single
0.021
1.822
1.095–3.034
0.016
1.862
1.120–3.096
BCLC
0.010
  
0.003
  
 B/A
0.621
0.873
0.509–1.496
0.822
0.941
0.552–1.603
 C/A
0.002
2.000
1.296–3.087
0.003
1.880
1.239–2.852
Child–Pugh
 B/A
0.082
0.665
0.420–1.053
   
AFP
  > 400 ng/ml/ ≤ 400 ng/ml
0.071
1.452
0.969–2.175
   
Edmondson-steiner
 IV/III/II/I
0.637
1.046
0.969–2.175
   
Necrosis
 Yes/no
0.485
0.872
0.867–1.263
   
Local invasion
Yes/no
0.002
1.718
0.592–1.282
0.001
1.686
1.223–2.323
ALB
 Per g
0.005
0.957
1.226–2.407
0.014
0.969
0.945–0.994
ALT
 Per U
0.007
0.990
0.927–0.987
 < 0.001
0.987
0.980–0.994
AST
 Per U
0.010
1.006
0.982–0.997
0.001
1.007
1.003–1.011
ALP
 Per U
0.024
1.002
1.001–1.010
0.030
1.002
1.000–1.003
GGT
 Per U
0.775
1.000
0.998–1.002
   
HBsAg
 Yes/no
0.242
0.736
0.440–1.230
   
Times of HIO
 < 0.001
  
 < 0.001
  
 1/0
0.298
1.215
0.842–1.752
0.495
1.130
0.795–1.606
 2/0
 < 0.001
4.522
2.542–8.045
 < 0.001
4.116
2.398–7.065
Blood loss
  > 400 ml/ ≤ 400 ml
0.023
1.322
1.182–1.744
0.144
1.288
0.892–1.286
BCLC, Barcelona Clinic Liver Cancer; AFP, alpha fetoprotein; ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT, γ-glutamyl transpeptidase; HIO, hepatic inflow occlusion
Table 6
Univariate and multivariate analysis to identify factors that predict recurrence-free survival in patients with ruptured hepatocellular carcinoma treated by hepatectomy
 
Univariate analysis
Multivariate analysis
p
HR
95%confidence interval
p
HR
95%confidence interval
Gender
 Male/female
0.872
1.044
0.648–1.883
   
Age
 Per year
0.470
0.994
0.983–1.013
   
Tumor length
 Per cm
0.001
1.981
1.096–2.779
0.001
1.932
1.295–2.881
Tumor number
 Mutiple/single
0.171
1.460
0.783–2.370
   
BCLC
0.118
     
 B/A
0.526
1.193
0.598–1.890
   
 C/A
0.039
1.594
0.927–2.254
   
Child–Pugh
 B/A
0.169
0.717
0.450–1.163
   
AFP
  > 400 ng/ml/ ≤ 400 ng/ml
0.112
1.312
0.812–1.823
   
Edmondson-steiner
 IV/III/II/I
0.323
1.099
0.830–1.204
   
Necrosis
 Yes/no
0.443
0.854
0.513–1.175
   
Local invasion
 Yes/no
0.078
1.363
0.929–1.864
   
ALB
 Per g
0.312
0.982
0.944–1.017
   
ALT
 Per U
0.165
0.995
0.989–1.002
   
AST
 Per U
0.224
1.002
0.998–1.006
   
ALP
 Per U
0.965
1.000
0.998–1.002
   
GGT
 Per U
0.001
1.004
1.002–1.006
 < 0.001
1.003
1.002–1.005
HBsAg
 Yes/no
0.468
0.826
0.408–1.162
   
Times of HIO
0.001
  
 < 0.001
  
 1/0
0.007
1.659
1.158–2.405
0.003
1.643
1.181–2.285
 2/0
0.001
2.604
1.505–4.491
 < 0.001
2.501
1.521–4.112
Blood loss
  > 400 ml/ ≤ 400 ml
0.003
1.454
1.092–1.626
0.082
1.276
0.926–1.427
BCLC, Barcelona Clinic Liver Cancer; AFP, alpha fetoprotein; ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT, γ-glutamyl transpeptidase; HIO, hepatic inflow occlusion
In addition, tumor length,number of tumors, BCLC stage, local invasion, ALB, ALT, AST, and ALP were also independent risk factors affecting OS; and GGT and tumor length were also independent risk factors affecting RFS.

Discussion

Rupture of liver cancer is a rare and serious complication of liver cancer with a high mortality rate. Although there are many treatment methods, such as TACE, intraperitoneal chemotherapy, surgical treatment, conservative treatment, etc., at present, the relatively better treatment is staged hepatectomy ( TACE for stage one treatment, followed by surgery as the second stage) [6]. Currently, there is an increasing number of research institutions discussing the risk factors affecting the postoperative survival of patients with ruptured HCC, hoping to find some prognostic factors to better manage rHCC patients [1820]. In hepatectomy for rHCC patients, we need to pay attention to the amount of bleeding during surgery, because some rHCC patients are inherently hemodynamically unstable. Surgeons usually use hepatic inflow occlusion techniques, including the Pringle Maneuver and hemihepatic vascular occlusion to control the amount of bleeding. By blocking the blood flow into the liver, intraoperative blood loss is greatly reduced and the probability of blood transfusion is also reduced [8, 9, 2123]. However, the adverse consequences of hepatic inflow occlusion should not be ignored. Both methods can cause postoperative liver function damage, and although some studies have indicated that HIO may not have an effect on the postoperative prognosis of HCC patients, the long-term survival rate of HIO in ruptured HCC patients is unknown, and the effect of the number of occlusion times on the prognosis is also unclear.
Previous studies have compared the Pringle Maneuver with hemihepatic blood flow occlusion, and there is still some controversy. In their meta-analysis, Wang et al. [23] found that the effects of the two techniques were not statistically different, but patients who were subjected to hemihepatic inflow occlusion had less liver injury. Similarly, Li et al. [24] and Chau et al. [15] found that hemihepatic inflow occlusion achieved similar results to the Pringle maneuver, but it had the advantage of reduced liver injury and better postoperative liver function recovery. While Yu et al. [25] concluded that the hemihepatic occlusion technique had the advantage of reduced operative time and blood loss, less injury, and better recovery when compared to the Pringle maneuver. In our study, the hepatic inflow occlusion method was selected according to the specific situation of the operator, and the blockage time was about 15 min each time. Although some studies indicated that hemihepatic blood flow blocking once could last for a longer time, considering that most patients had liver cirrhosis, the blockage time was set at about 15 min in our center. For patients with two blockages, the interval between each blockage was about 5 min.
Several previous retrospective studies [2629] showed that there was no significant difference in postoperative long-term survival between HIO and non-HIO groups in HCC patients. Similarly, a meta-analysis [23] compared the effect of vascular occlusion in liver surgery on postoperative HCC patients, and the results showed that HIO did not affect the postoperative overall survival. In our study, we specifically studied the effect of HIO in ruptured HCC patients after surgery, while further analyzing the effect of the number of blockages on long-term survival. Our results showed that one HIO had no effect on postoperative OS but had a negative effect on RFS in patients with rHCC; Overall, HIO negatively affected both the postoperative OS and the RFS in patients with rHCC, which is different from previous studies on patients with HCC. Ischemia during hepatic portal blood flow occlusion is one of the factors that can negatively affect the overall survival, and ischemia–reperfusion injury(IRI) after occlusion may also harm liver function [30, 31]. However, only one occlusion did not affect the OS in our study, while two occlusions were associated with a reduction in the OS. So the total number of occlusions and the composite effect of multiple ischemia–reperfusion injuries may also differently affect the OS. The main mechanisms through which HIO affects recurrence can also be summed up in two points: (1) ischemia destroys the adhesion between tumor and endothelial cells, resulting in microvascular injury, and reperfusion injury promotes metastasis and growth of tumor cells [3235]. (2) When in a blocked state, the pressure gradient between tumor vessels and portal vein can trigger cancer cells to detach from the main tumor, allowing tumor cells to translocate and spread.
Another point to note is why have most studies stated that HIO leads to tumor recurrence, while the conclusions for the postoperative OS of patients are very different? Lucinda Shen et al. [36] suggested that when performing HIO, they observed different blood flow responses of hepatic microvessels in different patients, which could also explain the different ischemia–reperfusion injury (IRI) effects on different patients when performing HIO, which in turn may lead to different postoperative OS’s. At the same time, it has been confirmed in some studies that changes in the circulation lead to heterogeneity in the response to IRI, and in livers with cirrhosis and fibrosis, the interaction between molecules disrupts the balance between cells and their surrounding matrix and also allows hepatic vascular remodeling. Many cells are involved in this process, including hepatic stellate cells, macrophages, and Kupffer cells. Hepatic endothelial cells are very important and help stabilize blood vessels. It is therefore necessary to develop techniques to perform intraoperative monitoring of hepatic microcirculation during hepatic inflow occlusions in the future [37].
Due to some selection or confounding bias, we also included all patient data in the multivariate Cox regression model, and the results showed that two times HIO was an independent risk factor affecting the postoperative OS of patients; HIO was an independent risk factor affecting the postoperative RFS of patients. In summary, our results suggest that HIO can affect the postoperative prognosis of ruptured HCC patients, but different blockage times will also affect the prognosis of patients differently.
This study has some limitations, namely: (1) This study is a retrospective study with some biases, and it is possible to perform a prospective study in the future to verify the conclusion. (2) The number of patients with ruptured HCC is relatively small, and the number of cases needs to be accumulated (3). Whether HIO affects postoperative complications has not been fully assessed, we need further investigation and follow-up.
In conclusion, HIO may affect the prognosis of patients with ruptured HCC, and the number of occlusion times can also affect the patients' prognosis. Although further RCTs are needed to validate this conclusion, in practical clinical work, we should consider the impact that HIO brings to patients with rHCC.

Acknowledgements

Not applicable.

Declarations

This research was performed in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology. All patients gave informed consent.The patients’ clinical and imaging information is the patients’ private data, and it is protected by Chinese laws. Therefore, the data and materials cannot be uploaded and shared with the public.
Written informed consent for publication was obtained from the patients and/or their legal guardians for publication.

Competing interests

The authors declare that they have no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Chen Z, Xie H, Hu M, Huang T, Hu Y, Sang N, Zhao Y. Recent progress in treatment of hepatocellular carcinoma. Am J Cancer Res. 2020;10(9):2993–3036.PubMedPubMedCentral Chen Z, Xie H, Hu M, Huang T, Hu Y, Sang N, Zhao Y. Recent progress in treatment of hepatocellular carcinoma. Am J Cancer Res. 2020;10(9):2993–3036.PubMedPubMedCentral
2.
Zurück zum Zitat Couri T, Pillai A. Goals and targets for personalized therapy for HCC. Hep Intl. 2019;13(2):125–37.CrossRef Couri T, Pillai A. Goals and targets for personalized therapy for HCC. Hep Intl. 2019;13(2):125–37.CrossRef
3.
Zurück zum Zitat Viveiros P, Riaz A, Lewandowski RJ, Mahalingam D. Current state of liver-directed therapies and combinatory approaches with systemic therapy in hepatocellular carcinoma (HCC). Cancers. 2019;11(8):1085.CrossRef Viveiros P, Riaz A, Lewandowski RJ, Mahalingam D. Current state of liver-directed therapies and combinatory approaches with systemic therapy in hepatocellular carcinoma (HCC). Cancers. 2019;11(8):1085.CrossRef
4.
Zurück zum Zitat Baskiran A, Akbulut S, Sahin TT, Koc C, Karakas S, Ince V, Yurdaydin C, Yilmaz S. Effect of HBV-HDV co-infection on HBV-HCC co-recurrence in patients undergoing living donor liver transplantation. Hep Intl. 2020;14(5):869–80.CrossRef Baskiran A, Akbulut S, Sahin TT, Koc C, Karakas S, Ince V, Yurdaydin C, Yilmaz S. Effect of HBV-HDV co-infection on HBV-HCC co-recurrence in patients undergoing living donor liver transplantation. Hep Intl. 2020;14(5):869–80.CrossRef
5.
Zurück zum Zitat Akbulut S, Koc C. Do we need to be limited by matching milan criteria for survival in living donor liver transplantation? J Gastrointest Cancer. 2020;51(4):1107–13.CrossRef Akbulut S, Koc C. Do we need to be limited by matching milan criteria for survival in living donor liver transplantation? J Gastrointest Cancer. 2020;51(4):1107–13.CrossRef
6.
Zurück zum Zitat Sahu SK, Chawla YK, Dhiman RK, Singh V, Duseja A, Taneja S, Kalra N, Gorsi U. Rupture of hepatocellular carcinoma: a review of literature. J Clin Exp Hepatol. 2019;9(2):245–56.CrossRef Sahu SK, Chawla YK, Dhiman RK, Singh V, Duseja A, Taneja S, Kalra N, Gorsi U. Rupture of hepatocellular carcinoma: a review of literature. J Clin Exp Hepatol. 2019;9(2):245–56.CrossRef
7.
Zurück zum Zitat Yoshida H, Mamada Y, Taniai N, Uchida E. Spontaneous ruptured hepatocellular carcinoma. Hepatol Res. 2016;46(1):13–21.CrossRef Yoshida H, Mamada Y, Taniai N, Uchida E. Spontaneous ruptured hepatocellular carcinoma. Hepatol Res. 2016;46(1):13–21.CrossRef
8.
Zurück zum Zitat Abdalla EK, Noun R, Belghiti J. Hepatic vascular occlusion: which technique? Surg Clin North Am. 2004;84(2):563–85.CrossRef Abdalla EK, Noun R, Belghiti J. Hepatic vascular occlusion: which technique? Surg Clin North Am. 2004;84(2):563–85.CrossRef
9.
Zurück zum Zitat Dixon E, Vollmer CM Jr, Bathe OF, Sutherland F. Vascular occlusion to decrease blood loss during hepatic resection. Am J Surg. 2005;190(1):75–86.CrossRef Dixon E, Vollmer CM Jr, Bathe OF, Sutherland F. Vascular occlusion to decrease blood loss during hepatic resection. Am J Surg. 2005;190(1):75–86.CrossRef
10.
Zurück zum Zitat Tranchart H, O’Rourke N, Van Dam R, Gaillard M, Lainas P, Sugioka A, Wakabayashi G, Dagher I. Bleeding control during laparoscopic liver resection: a review of literature. J Hepatobiliary Pancreat Sci. 2015;22(5):371–8.CrossRef Tranchart H, O’Rourke N, Van Dam R, Gaillard M, Lainas P, Sugioka A, Wakabayashi G, Dagher I. Bleeding control during laparoscopic liver resection: a review of literature. J Hepatobiliary Pancreat Sci. 2015;22(5):371–8.CrossRef
11.
Zurück zum Zitat Lei DX, Peng CH, Peng SY, Jiang XC, Wu YL, Shen HW. Safe upper limit of intermittent hepatic inflow occlusion for liver resection in cirrhotic rats. World J Gastroenterol. 2001;7(5):713–7.CrossRef Lei DX, Peng CH, Peng SY, Jiang XC, Wu YL, Shen HW. Safe upper limit of intermittent hepatic inflow occlusion for liver resection in cirrhotic rats. World J Gastroenterol. 2001;7(5):713–7.CrossRef
12.
Zurück zum Zitat Li CH, Chen YW, Chen YL, Yao LB, Ge XL, Pan K, Zhang AQ, Dong JH. Preserving low perfusion during surgical liver blood inflow control prevents hepatic microcirculatory dysfunction and irreversible hepatocyte injury in rats. Sci Rep. 2015;5:14406.CrossRef Li CH, Chen YW, Chen YL, Yao LB, Ge XL, Pan K, Zhang AQ, Dong JH. Preserving low perfusion during surgical liver blood inflow control prevents hepatic microcirculatory dysfunction and irreversible hepatocyte injury in rats. Sci Rep. 2015;5:14406.CrossRef
13.
Zurück zum Zitat van Riel WG, van Golen RF, Reiniers MJ, Heger M, van Gulik TM. How much ischemia can the liver tolerate during resection? Hepatobiliary Surg Nutr. 2016;5(1):58–71.PubMedPubMedCentral van Riel WG, van Golen RF, Reiniers MJ, Heger M, van Gulik TM. How much ischemia can the liver tolerate during resection? Hepatobiliary Surg Nutr. 2016;5(1):58–71.PubMedPubMedCentral
14.
Zurück zum Zitat Jiang JH, Wang KX, Zhu JY, Yang PP, Guo Z, Ma SL, Lü Y, Xiang BD, Zhong JH, Li LQ. Comparison of hepatectomy with or without hepatic inflow occlusion in patients with hepatocellular carcinoma: a single-center experience. Minerva Med. 2017;108(4):324–33.CrossRef Jiang JH, Wang KX, Zhu JY, Yang PP, Guo Z, Ma SL, Lü Y, Xiang BD, Zhong JH, Li LQ. Comparison of hepatectomy with or without hepatic inflow occlusion in patients with hepatocellular carcinoma: a single-center experience. Minerva Med. 2017;108(4):324–33.CrossRef
15.
Zurück zum Zitat Chau GY, Lui WY, King KL, Wu CW. Evaluation of effect of hemihepatic vascular occlusion and the Pringle maneuver during hepatic resection for patients with hepatocellular carcinoma and impaired liver function. World J Surg. 2005;29(11):1374–83.CrossRef Chau GY, Lui WY, King KL, Wu CW. Evaluation of effect of hemihepatic vascular occlusion and the Pringle maneuver during hepatic resection for patients with hepatocellular carcinoma and impaired liver function. World J Surg. 2005;29(11):1374–83.CrossRef
16.
Zurück zum Zitat van Gulik TM, de Graaf W, Dinant S, Busch OR, Gouma DJ. Vascular occlusion techniques during liver resection. Dig Surg. 2007;24(4):274–81.CrossRef van Gulik TM, de Graaf W, Dinant S, Busch OR, Gouma DJ. Vascular occlusion techniques during liver resection. Dig Surg. 2007;24(4):274–81.CrossRef
17.
Zurück zum Zitat Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.CrossRef Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.CrossRef
18.
Zurück zum Zitat Xu X, Chen C, Liu Q, Huang X. A meta-analysis of TAE/TACE versus emergency surgery in the treatment of ruptured HCC. Cardiovasc Intervent Radiol. 2020;43(9):1263–76.CrossRef Xu X, Chen C, Liu Q, Huang X. A meta-analysis of TAE/TACE versus emergency surgery in the treatment of ruptured HCC. Cardiovasc Intervent Radiol. 2020;43(9):1263–76.CrossRef
19.
Zurück zum Zitat Zhang W, Zhang ZW, Zhang BX, Huang ZY, Zhang WG, Liang HF, Chen XP. Outcomes and prognostic factors of spontaneously ruptured hepatocellular carcinoma. J Gastrointestinal Surg. 2019;23(9):1788–800.CrossRef Zhang W, Zhang ZW, Zhang BX, Huang ZY, Zhang WG, Liang HF, Chen XP. Outcomes and prognostic factors of spontaneously ruptured hepatocellular carcinoma. J Gastrointestinal Surg. 2019;23(9):1788–800.CrossRef
20.
Zurück zum Zitat Zou J, Li C, Chen Y, Chen R, Xue T, Xie X, Zhang L, Ren Z. Retrospective analysis of transcatheter arterial chemoembolization treatment for spontaneously ruptured hepatocellular carcinoma. Oncol Lett. 2019;18(6):6423–30.PubMedPubMedCentral Zou J, Li C, Chen Y, Chen R, Xue T, Xie X, Zhang L, Ren Z. Retrospective analysis of transcatheter arterial chemoembolization treatment for spontaneously ruptured hepatocellular carcinoma. Oncol Lett. 2019;18(6):6423–30.PubMedPubMedCentral
21.
Zurück zum Zitat Gurusamy KS, Sheth H, Kumar Y, Sharma D, Davidson BR. Methods of vascular occlusion for elective liver resections. Cochrane Database Syst Rev. 2009;1:cd007632. Gurusamy KS, Sheth H, Kumar Y, Sharma D, Davidson BR. Methods of vascular occlusion for elective liver resections. Cochrane Database Syst Rev. 2009;1:cd007632.
22.
Zurück zum Zitat Suzuki S, Inaba K, Konno H. Ischemic preconditioning in hepatic ischemia and reperfusion. Curr Opin Organ Transplant. 2008;13(2):142–7.CrossRef Suzuki S, Inaba K, Konno H. Ischemic preconditioning in hepatic ischemia and reperfusion. Curr Opin Organ Transplant. 2008;13(2):142–7.CrossRef
23.
Zurück zum Zitat Wang HQ, Yang JY, Yan LN. Hemihepatic versus total hepatic inflow occlusion during hepatectomy: a systematic review and meta-analysis. World J Gastroenterol. 2011;17(26):3158–64.PubMedPubMedCentral Wang HQ, Yang JY, Yan LN. Hemihepatic versus total hepatic inflow occlusion during hepatectomy: a systematic review and meta-analysis. World J Gastroenterol. 2011;17(26):3158–64.PubMedPubMedCentral
24.
Zurück zum Zitat Li M, Zhang T, Wang L, Li B, Ding Y, Zhang C, He S, Yang Z. Selective hemihepatic vascular occlusion versus pringle maneuver in hepatectomy for primary liver cancer. Med Sci Monitor. 2017;23:2203–10.CrossRef Li M, Zhang T, Wang L, Li B, Ding Y, Zhang C, He S, Yang Z. Selective hemihepatic vascular occlusion versus pringle maneuver in hepatectomy for primary liver cancer. Med Sci Monitor. 2017;23:2203–10.CrossRef
25.
Zurück zum Zitat Zhang Y, Yang H, Deng X, Chen Y, Zhu S, Kai C. Intermittent Pringle maneuver versus continuous hemihepatic vascular inflow occlusion using extra-glissonian approach in laparoscopic liver resection. Surg Endosc. 2016;30(3):961–70.CrossRef Zhang Y, Yang H, Deng X, Chen Y, Zhu S, Kai C. Intermittent Pringle maneuver versus continuous hemihepatic vascular inflow occlusion using extra-glissonian approach in laparoscopic liver resection. Surg Endosc. 2016;30(3):961–70.CrossRef
26.
Zurück zum Zitat Huang J, Tang W, Hernandez-Alejandro R, Bertens KA, Wu H, Liao M, Li J, Zeng Y. Intermittent hepatic inflow occlusion during partial hepatectomy for hepatocellular carcinoma does not shorten overall survival or increase the likelihood of tumor recurrence. Medicine. 2014;93(28):e288.CrossRef Huang J, Tang W, Hernandez-Alejandro R, Bertens KA, Wu H, Liao M, Li J, Zeng Y. Intermittent hepatic inflow occlusion during partial hepatectomy for hepatocellular carcinoma does not shorten overall survival or increase the likelihood of tumor recurrence. Medicine. 2014;93(28):e288.CrossRef
27.
Zurück zum Zitat Lan X, Li H, Liu F, Li B, Wei Y, Zhang H, Xu H. Does liver cirrhosis have an impact on the results of different hepatic inflow occlusion methods in laparoscopic liver resection? a propensity score analysis. HPB (Oxford). 2019;21(5):531–8.CrossRef Lan X, Li H, Liu F, Li B, Wei Y, Zhang H, Xu H. Does liver cirrhosis have an impact on the results of different hepatic inflow occlusion methods in laparoscopic liver resection? a propensity score analysis. HPB (Oxford). 2019;21(5):531–8.CrossRef
28.
Zurück zum Zitat Wei X, Zheng W, Yang Z, Liu H, Tang T, Li X, Liu X. Effect of the intermittent Pringle maneuver on liver damage after hepatectomy: a retrospective cohort study. World J Surg Oncol. 2019;17(1):142.CrossRef Wei X, Zheng W, Yang Z, Liu H, Tang T, Li X, Liu X. Effect of the intermittent Pringle maneuver on liver damage after hepatectomy: a retrospective cohort study. World J Surg Oncol. 2019;17(1):142.CrossRef
29.
Zurück zum Zitat Xu W, Xu H, Yang H, Liao W, Ge P, Ren J, Sang X, Lu X, Zhong S, Mao Y. Continuous Pringle maneuver does not affect outcomes of patients with hepatocellular carcinoma after curative resection. Asia Pac J Clin Oncol. 2017;13(5):e321–30.CrossRef Xu W, Xu H, Yang H, Liao W, Ge P, Ren J, Sang X, Lu X, Zhong S, Mao Y. Continuous Pringle maneuver does not affect outcomes of patients with hepatocellular carcinoma after curative resection. Asia Pac J Clin Oncol. 2017;13(5):e321–30.CrossRef
30.
Zurück zum Zitat Jiménez-Castro MB, Cornide-Petronio ME, Gracia-Sancho J, Peralta C. Inflammasome-mediated inflammation in liver ischemia-reperfusion injury. Cells. 2019;8(10):1131.CrossRef Jiménez-Castro MB, Cornide-Petronio ME, Gracia-Sancho J, Peralta C. Inflammasome-mediated inflammation in liver ischemia-reperfusion injury. Cells. 2019;8(10):1131.CrossRef
31.
Zurück zum Zitat Saidi RF, Kenari SK. Liver ischemia/reperfusion injury: an overview. J Investigative Surg. 2014;27(6):366–79.CrossRef Saidi RF, Kenari SK. Liver ischemia/reperfusion injury: an overview. J Investigative Surg. 2014;27(6):366–79.CrossRef
32.
Zurück zum Zitat Cotterell AH, Fisher RA. Ischemia/reperfusion injury and hepatocellular carcinoma recurrence after liver transplantation: cancer at WIT’s End? Dig Dis Sci. 2015;60(9):2579–80.CrossRef Cotterell AH, Fisher RA. Ischemia/reperfusion injury and hepatocellular carcinoma recurrence after liver transplantation: cancer at WIT’s End? Dig Dis Sci. 2015;60(9):2579–80.CrossRef
33.
Zurück zum Zitat Grąt M, Krawczyk M, Wronka KM, Stypułkowski J, Lewandowski Z, Wasilewicz M, Krawczyk P, Grąt K, Patkowski W, Zieniewicz K. Ischemia-reperfusion injury and the risk of hepatocellular carcinoma recurrence after deceased donor liver transplantation. Sci Rep. 2018;8(1):8935.CrossRef Grąt M, Krawczyk M, Wronka KM, Stypułkowski J, Lewandowski Z, Wasilewicz M, Krawczyk P, Grąt K, Patkowski W, Zieniewicz K. Ischemia-reperfusion injury and the risk of hepatocellular carcinoma recurrence after deceased donor liver transplantation. Sci Rep. 2018;8(1):8935.CrossRef
34.
Zurück zum Zitat Man K, Ng KT, Lo CM, Ho JW, Sun BS, Sun CK, Lee TK, Poon RT, Fan ST. Ischemia-reperfusion of small liver remnant promotes liver tumor growth and metastases–activation of cell invasion and migration pathways. Liver Transplant. 2007;13(12):1669–77.CrossRef Man K, Ng KT, Lo CM, Ho JW, Sun BS, Sun CK, Lee TK, Poon RT, Fan ST. Ischemia-reperfusion of small liver remnant promotes liver tumor growth and metastases–activation of cell invasion and migration pathways. Liver Transplant. 2007;13(12):1669–77.CrossRef
35.
Zurück zum Zitat Theodoraki K, Papadoliopoulou M, Petropoulou Z, Theodosopoulos T, Vassiliu P, Polydorou A, Xanthakos P, Fragulidis G, Smyrniotis V, Arkadopoulos N. Does vascular occlusion in liver resections predispose to recurrence of malignancy in the liver remnant due to ischemia/reperfusion injury? A comparative retrospective cohort study. Int J Surgery (London, England). 2020;80:68–73.CrossRef Theodoraki K, Papadoliopoulou M, Petropoulou Z, Theodosopoulos T, Vassiliu P, Polydorou A, Xanthakos P, Fragulidis G, Smyrniotis V, Arkadopoulos N. Does vascular occlusion in liver resections predispose to recurrence of malignancy in the liver remnant due to ischemia/reperfusion injury? A comparative retrospective cohort study. Int J Surgery (London, England). 2020;80:68–73.CrossRef
36.
Zurück zum Zitat Shen L, Uz Z, Verheij J, Veelo DP, Ince Y, Ince C, van Gulik TM. Interpatient heterogeneity in hepatic microvascular blood flow during vascular inflow occlusion (Pringle manoeuvre). Hepatobiliary Surg Nutr. 2020;9(3):271–83.CrossRef Shen L, Uz Z, Verheij J, Veelo DP, Ince Y, Ince C, van Gulik TM. Interpatient heterogeneity in hepatic microvascular blood flow during vascular inflow occlusion (Pringle manoeuvre). Hepatobiliary Surg Nutr. 2020;9(3):271–83.CrossRef
37.
Zurück zum Zitat Xia F, Ndhlovu E, Zhang M, Chen X, Zhang B, Zhu P. Ruptured hepatocellular carcinoma: current status of research. Front Oncol. 2022;12:848903.CrossRef Xia F, Ndhlovu E, Zhang M, Chen X, Zhang B, Zhu P. Ruptured hepatocellular carcinoma: current status of research. Front Oncol. 2022;12:848903.CrossRef
Metadaten
Titel
The effect of the number of hepatic inflow occlusion times on the prognosis of ruptured hepatocellular carcinoma patients after hepatectomy
verfasst von
Feng Xia
Zhiyuan Huang
Elijah Ndhlovu
Mingyu Zhang
Xiaoping Chen
Bixiang Zhang
Peng Zhu
Publikationsdatum
01.12.2022
Verlag
BioMed Central
Erschienen in
BMC Surgery / Ausgabe 1/2022
Elektronische ISSN: 1471-2482
DOI
https://doi.org/10.1186/s12893-022-01537-8

Weitere Artikel der Ausgabe 1/2022

BMC Surgery 1/2022 Zur Ausgabe

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Deutlich weniger Infektionen: Wundprotektoren schützen!

08.05.2024 Postoperative Wundinfektion Nachrichten

Der Einsatz von Wundprotektoren bei offenen Eingriffen am unteren Gastrointestinaltrakt schützt vor Infektionen im Op.-Gebiet – und dient darüber hinaus der besseren Sicht. Das bestätigt mit großer Robustheit eine randomisierte Studie im Fachblatt JAMA Surgery.

Chirurginnen und Chirurgen sind stark suizidgefährdet

07.05.2024 Suizid Nachrichten

Der belastende Arbeitsalltag wirkt sich negativ auf die psychische Gesundheit der Angehörigen ärztlicher Berufsgruppen aus. Chirurginnen und Chirurgen bilden da keine Ausnahme, im Gegenteil.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.